Literature DB >> 18673210

Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

W Lee Titsworth1, Nai-Kui Liu, Xiao-Ming Xu.   

Abstract

Secretory phospholipases A(2) (sPLA(2)s) are a subfamily of lipolytic enzymes which hydrolyze the acyl bond at the sn-2 position of glycerophospholipids to produce free fatty acids and lysophospholipids. These products are precursors of bioactive eicosanoids and platelet-activating factor (PAF). The hydrolysis of membrane phospholipids by PLA(2) is a rate-limiting step for generation of eicosanoids and PAF. To date, more than 10 isozymes of sPLA(2) have been found in the mammalian central nervous system (CNS). Under physiological conditions, sPLA(2)s are involved in diverse cellular responses, including host defense, phospholipid digestion and metabolism. However, under pathological situations, increased sPLA(2) activity and excessive production of free fatty acids and their metabolites may lead to inflammation, loss of membrane integrity, oxidative stress, and subsequent tissue injury. Emerging evidence suggests that sPLA(2) plays a role in the secondary injury process after traumatic or ischemic injuries in the brain and spinal cord. Importantly, sPLA(2) may act as a convergence molecule that mediates multiple key mechanisms involved in the secondary injury since it can be induced by multiple toxic factors such as inflammatory cytokines, free radicals, and excitatory amino acids, and its activation and metabolites can exacerbate the secondary injury. Blocking sPLA(2) action may represent a novel and efficient strategy to block multiple injury pathways associated with the CNS secondary injury. This review outlines the current knowledge of sPLA(2) in the CNS with emphasis placed on the possible roles of sPLA(2) in mediating CNS injuries, particularly the traumatic and ischemic injuries in the brain and spinal cord.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18673210      PMCID: PMC2800081          DOI: 10.2174/187152708784936671

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  260 in total

1.  Cloning and recombinant expression of a novel mouse-secreted phospholipase A2.

Authors:  E Valentin; R S Koduri; J C Scimeca; G Carle; M H Gelb; M Lazdunski; G Lambeau
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

2.  Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury.

Authors:  R D Azbill; X Mu; A J Bruce-Keller; M P Mattson; J E Springer
Journal:  Brain Res       Date:  1997-08-15       Impact factor: 3.252

Review 3.  Inhibitors of secretory phospholipase A2 group IIA.

Authors:  Robert C Reid
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

4.  Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Brain Res       Date:  2007-01-03       Impact factor: 3.252

5.  Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain.

Authors:  D T Stephenson; C A Lemere; D J Selkoe; J A Clemens
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

6.  Cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC): response to genistein and pyrrolidine dithiocarbamate.

Authors:  W Li; J Xia; G Y Sun
Journal:  J Interferon Cytokine Res       Date:  1999-02       Impact factor: 2.607

7.  The phospholipase A2 inhibitor quinacrine prevents increased immunoreactivity to cytoplasmic phospholipase A2 (cPLA2) and hydroxynonenal (HNE) in neurons of the lateral septum following fimbria-fornix transection.

Authors:  X R Lu; W Y Ong; B Halliwell
Journal:  Exp Brain Res       Date:  2001-06       Impact factor: 1.972

8.  Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.

Authors:  N Leitinger; A D Watson; S Y Hama; B Ivandic; J H Qiao; J Huber; K F Faull; D S Grass; M Navab; A M Fogelman; F C de Beer; A J Lusis; J A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-05       Impact factor: 8.311

9.  Serum phospholipases A2 after aortobifemoral reconstruction.

Authors:  J M Grönroos; K Kuttila; J Perttilä; T J Nevalainen
Journal:  Eur J Clin Chem Clin Biochem       Date:  1995-05

10.  The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia.

Authors:  M MacPhee; K P Chepenik; R A Liddell; K K Nelson; L D Siracusa; A M Buchberg
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

View more
  18 in total

1.  Stability, disposition, and penetration of catalytic antioxidants Mn-porphyrin and Mn-salen and of methylprednisolone in spinal cord injury.

Authors:  Liqin Wu; Yichu Shan; Danxia Liu
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-06

Review 2.  Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Authors:  Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 3.  Phospholipases A2 and neural membrane dynamics: implications for Alzheimer's disease.

Authors:  James C-M Lee; Agnes Simonyi; Albert Y Sun; Grace Y Sun
Journal:  J Neurochem       Date:  2011-01-07       Impact factor: 5.372

4.  Matrix-Assisted Laser Desorption Ionization Mapping of Lysophosphatidic Acid Changes after Traumatic Brain Injury and the Relationship to Cellular Pathology.

Authors:  Whitney S McDonald; Elizabeth E Jones; Jonathan M Wojciak; Richard R Drake; Roger A Sabbadini; Neil G Harris
Journal:  Am J Pathol       Date:  2018-07-16       Impact factor: 4.307

5.  High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal dieback in traumatic spinal cord injury.

Authors:  Teresa A Evans; Deborah S Barkauskas; Jay T Myers; Elisabeth G Hare; Jing Qiang You; Richard M Ransohoff; Alex Y Huang; Jerry Silver
Journal:  Exp Neurol       Date:  2014-01-24       Impact factor: 5.330

6.  Distribution of secretory phospholipase A2 XIIA in the brain and its role in lipid metabolism and cognition.

Authors:  Sze-Min Ee; Yew-Long Lo; Guanghou Shui; Markus R Wenk; Eun-Joo Shin; Hyoung-Chun Kim; Wei-Yi Ong
Journal:  Mol Neurobiol       Date:  2014-01-25       Impact factor: 5.590

Review 7.  Phospholipases A2 and inflammatory responses in the central nervous system.

Authors:  Grace Y Sun; Phullara B Shelat; Michael B Jensen; Yan He; Albert Y Sun; Agnes Simonyi
Journal:  Neuromolecular Med       Date:  2009-10-24       Impact factor: 3.843

8.  Secreted phospholipase A2 involvement in neurodegeneration: differential testing of prosurvival and anti-inflammatory effects of enzyme inhibition.

Authors:  Shuyan Chen; Lihua Yao; Timothy J Cunningham
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

9.  Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury.

Authors:  Nai-Kui Liu; Ling-Xiao Deng; Yi Ping Zhang; Qing-Bo Lu; Xiao-Fei Wang; Jian-Guo Hu; Eddie Oakes; Joseph V Bonventre; Christopher B Shields; Xiao-Ming Xu
Journal:  Ann Neurol       Date:  2014-04-02       Impact factor: 10.422

10.  The proteome of the differentiating mesencephalic progenitor cell line CSM14.1 in vitro.

Authors:  B Weiss; S Haas; G Lessner; S Mikkat; M Kreutzer; M O Glocker; A Wree; O Schmitt
Journal:  Biomed Res Int       Date:  2014-01-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.